Formulation and optimization of itraconazole polymeric lipid hybrid nanoparticles (Lipomer) using box behnken design

DARU, Journal of Pharmaceutical Sciences

Volumn 23, Issue 1, 2015, Pages

  Gajra, Balaram ^a   Dalwadi, Chintan ^a   Patel, Ravi ^b  

^a CHAROTAR UNIVERSITY OF SCIENCE AND TECHNOLOGY   (India)

^b BANARAS HINDU UNIVERSITY   (India)

Author keywords

Box behnken design; Drug loading; Entrapment efficiency; Optimization; Polymeric lipid hybrid nanoparticles

Indexed keywords

ITRACONAZOLE; LIPOSOME; NANOPARTICLE; PHOSPHATIDYLCHOLINE; POLYCAPROLACTONE; POLYMERIC LIPID HYBRID NANOPARTICLE; POLYVINYL ALCOHOL; UNCLASSIFIED DRUG; ANTIFUNGAL AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONCENTRATION (PARAMETERS); CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG FORMULATION; DRUG PENETRATION; EMULSION; EVAPORATION; HYDROPHOBICITY; INTESTINE MUCOSA PERMEABILITY; MALE; NANOENCAPSULATION; NANOPHARMACEUTICS; NONHUMAN; PARTICLE SIZE; PREDICTION; RAT; SOLVENT EFFECT; SURFACE CHARGE; ZETA POTENTIAL; ANIMAL; CHEMISTRY; INTESTINE; MEDICINAL CHEMISTRY; METABOLISM; PROCEDURES; SURFACE PROPERTY; SYNTHESIS; ULTRASTRUCTURE; WISTAR RAT;

ANIMALS; ANTIFUNGAL AGENTS; CHEMISTRY, PHARMACEUTICAL; DRUG COMPOUNDING; INTESTINES; ITRACONAZOLE; LIPOSOMES; MALE; NANOPARTICLES; PARTICLE SIZE; RATS; RATS, WISTAR; SURFACE PROPERTIES;

EID: 84989181070     PISSN: 15608115     EISSN: 20082231     Source Type: Journal    
DOI: 10.1186/s40199-014-0087-0     Document Type: Article

References (34)

1. Rkumar A. Robbins and cotran pathologic basic of disease. 8th ed. New Delhi, India: Elsevier; 2007. p. 320-50.
2. Six K, Daemsa T, Jd H. Clinical study of solid dispersions of itraconazole prepared by hot-stage extrusion. Eur J Pharm Sci. 2005;24:179-86.
3. Kim J-K, Parkb J-S, Kima C-K. Development of a binary lipid nanoparticles formulation of itraconazole for parenteral administration and controlled release. Int J Pharm. 2010;383:209-15.
4. Chen W, Gua B, Wang H. Development and evaluation of novel itraconazole-loaded intravenous nanoparticles. Int J Pharm. 2008;362:133-40.
5. Valencia PM, Basto PA, Zha L. Single-step assembly of homogenous lipid polymeric and lipid quantum dot nanoparticles enabled by microfluidic rapid mixing. Am Chem Soc. 2010;4:1671-9.
6. Clark MA, Jepson MA. Exploiting M cells for drug and vaccine delivery. Adv Drug Deliv Rev. 2001;50:81-106.
7. Lopes MA, Abrahim BA. Intestinal absorption of insulin nanoparticles: contribution of M cells. Nanomedicine. 2014;10:1139-51.
8. Shrestha N, Shahbazi M-A. Chitosan-modified porous silicon microparticles for enhanced permeability of insulin across intestinal cell monolayers. Biomaterials. 2014;35:7172-9.
9. Lee H, Jeong C, Ghafoor K. Oral delivery of insulin using chitosan capsules cross-linked with phytic acid. Biomed Mater Eng. 2011;21:25-36.
10. Li H, Zhao X. Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles. J Control Release. 2009;133:238-44.
11. Zakeri-Milani P, Loveymi BD. The characteristics and improved intestinal permeability of vancomycin PLGA-nanoparticles as colloidal drug delivery system. Colloids Surf B: Biointerfaces. 2013;103:174-81.
12. Mazzaferro S, Bouchemal K. Intestinal permeation enhancement of docetaxel encapsulated into methyl-β-cyclodextrin/poly(isobutylcyanoacrylate) nanoparticles coated with thiolated chitosan. J Control Release. 2012;162:568-74.
13. Liu Y, Di Zang H. In vitro evaluation of mucoadhesion and permeation enhancement of polymeric amphiphilic nanoparticles. Carbohydr Polym. 2012;89:453-60.
14. Kogaa K, Takarada N. Nano-sized water-in-oil-in-water emulsion enhances intestinal absorption of calcein, a high solubility and low permeability compound. Eur J Pharm Biopharm. 2010;74:223-32.
15. Zhang L, Chan JM, Gu FX. Self-assembled lipid polymer hybrid nanoparticles: a robust drug delivery platform. J Am Chem Soc. 2008;2:1696-702.
16. Cheow WS, Hadinoto K. Factors affecting drug encapsulation and stability of lipid-polymer hybrid nanoparticles. Colloids Surf B: Biointerfaces. 2011;85:214-20.
17. Zhang L. Lipid polymer hybrid nanoparticles: synthesis, characterization and applications. World Sci Publishing Company. 2010;1:163-73.
18. Ferreira SL, Bruns RE, Ferreira HS. Box-behnken design: an alternative for the optimization of analytical methods. Anal Chim Acta. 2007;597:179-86.
19. Solanki AB, Parikh JR, Parikh RH. Formulation and optimization of piroxicam proniosomes by 3-factor, 3-level box-behnken design. AAPS Pharm Sci Tech. 2007;8(4):E86.
20. Devarajan PV, Benival DM. Lipomer of doxorubicin hydrochloride for enhanced oral bioavailability. Int J Pharm. 2012;423:554-61.
21. Jain S, Jain AK, Swarnakar NK. The effect of the oral administration of polymeric nanoparticles on the efficacy and toxicity of tamoxifen. Biomaterials. 2011;32:503-15.
22. Ling G, Zhang P, Zhang W. Development of novel self-assembled DS-PLGA hybrid nanoparticles for improving oral bioavailability of vincristine sulfate by P-gp inhibition. J Control Release. 2010;148:241-8.
23. Li Y, Wong HL, Shuhendler AJ. Molecular interactions, internal structure and drug release kinetics of rationally developed polymer-lipid hybrid nanoparticles. J Control Release. 2008;128:60-70.
24. Watanabe ETM, Hayashi M. A possibility to predict the absorbability of poor water-soluble drugs in humans based on the rat intestinal permeability assessed by an in vitro chamber method. Eur J Pharm Biopharm. 2004;58:659-65.
25. Mukherjee S, Ray S, Thakur R. Design and evaluation of itraconazole loaded solid lipid nanoparticulate system for improving the antifungal therapy. Pak J Pharm Sci. 2009;22:131-8.
26. Hillgren KM, Kato A, Borchardt RT. In vitro systems for studying intestinal drug absorption. Med Res Rev. 1995;15:83-109.
27. Wong HL, Bendayan R, Rauth AM. A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system. J Pharmacol Exp Ther. 2006;317:1372-81.
28. Belletti D, Rivab G, Tosia G. Novel polymeric/lipidic hybrid systems (PLHs) for effective cidofovir delivery: preparation, characterization and comparative in vitro study with polymeric particles and liposomes. Int J Pharm. 2011;413:220-8.
29. Yang W, Chow KT, Lang B. In vitro characterization and pharmacokinetics in mice following pulmonary delivery of itraconazole as cyclodextrin solubilized solution. Eur J Pharm Sci. 2010;39:336-47.
30. Singhvi G, Singh M. Review: in-vitro drug release characterization models. Int J Pharm Stud Res. 2011;2:77-84.
31. Paulo Costa JML. Modeling and comparison of dissolution profiles. Eur J Pharm Sci. 2001;13:123-33.
32. Wei S, Shirui M, Shi Y. Nanonisation of itraconazole by high pressure homoginisation: stabiliser optimization and effext of particle size on oral absorption. J Pharm Sci. 2011;100:3365-73.
33. Sahoo SK, Panyama J, Prabha S. Residual polyvinyl alcohol associated with poly (D, L-lactide-coglycolide) nanoparticles affects their physical properties and cellular uptake. J Control Release. 2002;82:105-14.
34. Prakobvaitayakit M, Nimmannit U. Optimization of polylactic-co-glycolic acid nanoparticles containing itra-conazole using 23 factorial design. AAPS Pharm SciTech. 2003;4:565-73.